As part of the deal, Liomont will seek regulatory approval for Flublok in Mexico and initially sell the product manufactured by Protein Sciences.
Liomont has also secured rights to manufacture Flublok and Panblok in Mexico.
In return, Protein Sciences is entitled to significant license and milestone payments and double-digit royalties on sales.
Liomont CEO Alfredo Rimoch said the revolutionary nature and broad technology platform behind Flublok and Panblok afford these vaccines important advantages over other vaccines on the market – both can be made safely, accurately and much faster than other vaccines.
"Flublok and Panblok complement our pipeline as we look into building a solid biotech portfolio which we can market in Latin America by 2015," Rimoch said.
"Most importantly, the modern recombinant technology behind the products will allow us to rapidly supply the Mexican market with an effective pandemic influenza vaccine if and when the need arises."
Protein Sciences executive chairman and global head of Business Development Dan Adams said the partnership with Liomont will make Flublok broadly available to the company’s Southern neighbors.
"Flublok represents a breakthrough in vaccine technology, and we will continue to work with partners like Liomont to make the vaccine and our technology available globally," Adams said.